Novogenia AG Reports H1 2026 Performance and Strategic Advances

Novogenia AG, a Munich-based healthcare firm, shared its H1 2026 issuer report, highlighting strategic growth despite financial underperformance. The company, previously Darwin AG, noted a 7% drop in revenue, totaling EUR 25.7 million, due to regulatory impacts on pharmaceuticals. Yet, its DNA analysis sector showed year-on-year growth. Operating profits improved by EUR 2.7 million through cost savings, though EBIT rose slightly to EUR -4.7 million.

The firm's strategic progress included expanding its U.S. product line with Methylation Test MGT Plus and preparing for a Middle East market entry with Halal certification. Infrastructure investments and a name change to Novogenia AG aim to consolidate its brand. The participation in upcoming conferences signals Novogenia's intent to enhance its market presence globally, despite challenges.